Cargando…
Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer
IMPORTANCE: Neoadjuvant therapy is increasingly used in localized pancreatic carcinoma, and survival is correlated with carbohydrate antigen 19-9 (CA19-9) levels and histopathologic response following neoadjuvant therapy. With several regimens now available, the choice of chemotherapy could be best...
Autores principales: | AlMasri, Samer, Zenati, Mazen, Hammad, Abdulrahman, Nassour, Ibrahim, Liu, Hao, Hogg, Melissa E., Zeh, Herbert J., Boone, Brian, Bahary, Nathan, Singhi, Aatur D., Lee, Kenneth K., Paniccia, Alessandro, Zureikat, Amer H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227002/ https://www.ncbi.nlm.nih.gov/pubmed/35737385 http://dx.doi.org/10.1001/jamanetworkopen.2022.18355 |
Ejemplares similares
-
Encouraging long‐term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high‐risk patients with resectable pancreatic carcinoma
por: AlMasri, Samer S., et al.
Publicado: (2021) -
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma
por: Fei, Naomi, et al.
Publicado: (2021) -
Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies
por: Dhir, Mashaal, et al.
Publicado: (2016) -
An Unexpected Etiology of Pancreatic Panniculitis: A Case Report
por: Evans, Anna C., et al.
Publicado: (2017) -
Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age
por: Chao, David T., et al.
Publicado: (2018)